This week's roundup of Houston innovators includes Kevin Coker of Proxima CRO, Gaurab Chakrabarti of Solugen, and Phil Sitter and Chris Chomenko of RepeatMD. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to four local innovators across industries — from marketing tech to synthetic biology — recently making headlines in Houston innovation.

Kevin Coker, CEO and co-founder of Proxima CRO, and Gaurab Chakrabarti, CEO and co-founder of Solugen

First Bight VC named two Houstonians to its board. Photos courtesy

First Bight Ventures, a new VC firm focused exclusively on early-stage synthetic biology startups founded by Veronica Wu in January, has named two new board members: Gaurab Chakrabarti, co-founder and CEO of Solugen, and Kevin Cocker, co-founder and CEO of Proxima CRO.

"We are excited to announce the addition of Dr. Gaurab Chakrabarti and Kevin Cocker," Wu says in a press release. "These two advisors are experts in their respective fields of medicine and biotechnology. They are proven leaders of Houston-based companies, which is key to our overall growth strategy, as we seek to establish Houston as a geographic center for innovation in Synthetic Biology." Click here to read more.

RepeatMD's CEO Phil Sitter and Vice President of Sales Chris Chomenko

RepeatMD's CEO Phil Sitter and Vice President of Sales Chris Chomenko join the Houston Innovators Podcast to explain how they are revolutionizing the aesthetics industry. Photos courtesy

Houston restaurateur pivoted his restaurant marketing business amid the pandemic — to a growing industry: aesthetics. Phil Sitter took the idea and tech he created with VIPInsiders to launch RepeatMD, a customizable marketing and fintech platform focused on the aesthetics industry, which includes plastic surgeons, dermatologists, etc.

Sitter, who serves as the company's CEO, says once he dived into learning about the industry, he found out these types of business are seeing incredible growth following the pandemic.

"They call it the 'Zoom boom' — everyone saw themselves on Zoom daily and decided to invest in themselves and their facial treatments." says Chris Chomenko, vice president of sales for the company, on the Houston Innovators Podcast.

"And they had the time," Sitter adds. "When you think about aesthetic procedures — whether its invasive or non-invasive, it takes time for recovery." Click here to read more.

RepeatMD's CEO Phil Sitter and Vice President of Sales Chris Chomenko join the Houston Innovators Podcast to explain how they are revolutionizing the aesthetics industry. Photos courtesy

Houston innovators find 'perfect storm' for fintech and marketing platform

Houston innovators podcast episode 129

Phil Sitter saw fast growth and adoption from his restaurant rewards platform he founded in 2019, but when the pandemic hit, he had to go back to the drawing board to find a growing industry that needed to be disrupted by his technology. And he did.

Sitter, a Houston restaurateur, originally founded VIPInsiders to help his restaurants — and later, licensing the technology out, other Houston eateries too — reward loyal patrons who continue to come in. However, in 2020, Sitter considered a pivot.

"We realized the restaurant industry may never be the same, and we asked ourselves who could be an ideal client," Sitter says on the Houston Innovators Podcast.

This pivot ended up creating RepeatMD, a customizable marketing and fintech platform focused on the aesthetics industry, which includes plastic surgeons, dermatologists, etc.

Sitter, who serves as the company's CEO, says once he dived into learning about the industry, he found out these types of business are seeing incredible growth following the pandemic.

"They call it the 'Zoom boom' — everyone saw themselves on Zoom daily and decided to invest in themselves and their facial treatments." says Chris Chomenko, vice president of sales for the company.

"And they had the time," Sitter adds. "When you think about aesthetic procedures — whether its invasive or non-invasive, it takes time for recovery."

After initially branching out into the field, Sitter says they are now onboarding up to 200 new locations a month, providing med spas around the world the ability to reward returning customers, as well as inform them on the breadth of options the facility offers. RepeatMD has expanded its team to 50 people and is eyeing seed funding this summer.

"Some things had to work out perfectly in order," Chomenko says, "for this perfect storm of perfect timing. Whenever you talk about entrepreneurs and how much of it was luck and how much of it is hard work, we really have attribute a lot of our success to being there with the right idea, in the right place, at the right time."

Sitter and Chomenko share more about the future of RepeatMD on the podcast episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

RepeatMD offers its clients rewards-based software and is expanding with a new fintech tool. Photo via Getty Images

Fast-growing Houston software startup expands with fintech model

innovative marketing

A less than one-year-old B2B software startup in Houston is beefing up its offerings with a new feature that thrusts it into the rapidly growing fintech space.

RepeatMD, founded in December 2020, specializes in white-label rewards apps for plastic surgeons, medical spas, dermatologists, and similar businesses. Now, it's expanding into the "buy now, pay later" fintech realm through a new deal with BTL Industries, a Marlborough, Massachusetts-based provider of body-sculpting equipment.

RepeatMD's new Medical Gym function enables customers treated with BTL equipment to finance add-on enhancement and maintenance packages through "buy now, pay later" (BNPL) arrangements. BNPL is a booming sector. The size of the global BNPL market approached $90.7 billion in 2020 and is projected to come close to $4 trillion by 2030, according to Allied Market Research.

RepeatMD essentially layers the Medical Gym's BNPL functionality on top of the rewards feature of its apps.

Chris Chomenko, vice president of sales at RepeatMD, says the startup already had been working on a BNPL offering when BTL approached the RepeatMD team about creating a BNPL product. RepeatMD and BTL share many of the same clients.

"We are rolling out with them nationally at a breakneck speed because the demand they have from their client base is so high," Chomenko says. "It's kind of forcing us to do in three months what we planned on doing in three years."

While the concept of a rewards app or a BNPL program is not unique, their pairing is, according to Chomenko. Sitter calls the marriage of the two a "game changer" — a game changer that eventually should extend well beyond BTL's clients.

RepeatMD founder and CEO Philipp Sitter says the Medical Gym feature lets customers break up the cost of, say, a $5,000 treatment into management monthly payments. The results of a survey of RepeatMD app users found that the guilt of putting down a wad of cash on aesthetics services was the No. 2 barrier cited in terms of spending money on treatments.

"What we'll be working on is being a full, proper fintech play, where we have that buy now, pay later functionality, and doctors can get paid in advance for treatments. But that is a large endeavor that will take us all of a year to [complete]," Chomenko says.

RepeatMD counts more than 600 practices in North America as customers. The startup envisions that figure rising to 1,000 by the end of this year. In tandem with that growth, RepeatMD foresees revenue climbing to eight figures (at least $10 million) by the end of 2022 and its valuation growing to nine figures (at least $100 million) by then.

Today, RepeatMD employs about 30 people. Sitter says the headcount should reach 75 to 100 by the end of next year.

Sitter is self-funding RepeatMD with proceeds from other business ventures, including Houston-based food and beverage loyalty and rewards platform VIPinsiders and Houston-based brunch and lunch restaurant EggHaus Gourmet. However, RepeatMD plans to raise outside capital in the first quarter of 2022.

The company sets up each client with an exclusive private-label app. RepeatMD says businesses using its app have seen an average sales increase of $313,000 and an average of 51 new referrals within the first 90 days of adopting the app.

Sitter says the RepeatMD rewards app provides a "gateway" for businesses to drum up repeat business and sell more services, much like the Starbucks rewards app incentivizes customers to try different food and beverage products.

"We see us becoming ubiquitous in the industry, where anybody that's a dermatologist, a plastic surgeon, or a medical spa has [our app]," Sitter says.

"We look at mobile app experience as something that's coming for all the local businesses. We're just the frontrunners in bringing it to the masses," he adds.

Philipp Sitter is the founder of RepeatMD. Photo via LinkedIIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston doctor wins NIH grant to test virtual reality for ICU delirium

Virtual healing

Think of it like a reverse version of The Matrix. A person wakes up in a hospital bed and gets plugged into a virtual reality game world in order to heal.

While it may sound far-fetched, Dr. Hina Faisal, a Houston Methodist critical care specialist in the Department of Surgery, was recently awarded a $242,000 grant from the National Institute of Health to test the effects of VR games on patients coming out of major surgery in the intensive care unit (ICU).

The five-year study will focus on older patients using mental stimulation techniques to reduce incidences of delirium. The award comes courtesy of the National Institute on Aging K76 Paul B. Beeson Emerging Leaders Career Development Award in Aging.

“As the population of older adults continues to grow, the need for effective, scalable interventions to prevent postoperative complications like delirium is more important than ever,” Faisal said in a news release.

ICU delirium is a serious condition that can lead to major complications and even death. Roughly 87 percent of patients who undergo major surgery involving intubation will experience some form of delirium coming out of anesthesia. Causes can range from infection to drug reactions. While many cases are mild, prolonged ICU delirium may prevent a patient from following medical advice or even cause them to hurt themselves.

Using VR games to treat delirium is a rapidly emerging and exciting branch of medicine. Studies show that VR games can help promote mental activity, memory and cognitive function. However, the full benefits are currently unknown as studies have been hampered by small patient populations.

Faisal believes that half of all ICU delirium cases are preventable through VR treatment. Currently, a general lack of knowledge and resources has been holding back the advancement of the treatment.

Hopefully, the work of Faisal in one of the busiest medical cities in the world can alleviate that problem as she spends the next half-decade plugging patients into games to aid in their healing.

Houston scientists develop breakthrough AI-driven process to design, decode genetic circuits

biotech breakthrough

Researchers at Rice University have developed an innovative process that uses artificial intelligence to better understand complex genetic circuits.

A study, published in the journal Nature, shows how the new technique, known as “Combining Long- and Short-range Sequencing to Investigate Genetic Complexity,” or CLASSIC, can generate and test millions of DNA designs at the same time, which, according to Rice.

The work was led by Rice’s Caleb Bashor, deputy director for the Rice Synthetic Biology Institute and member of the Ken Kennedy Institute. Bashor has been working with Kshitij Rai and Ronan O’Connell, co-first authors on the study, on the CLASSIC for over four years, according to a news release.

“Our work is the first demonstration that you can use AI for designing these circuits,” Bashor said in the release.

Genetic circuits program cells to perform specific functions. Finding the circuit that matches a desired function or performance "can be like looking for a needle in a haystack," Bashor explained. This work looked to find a solution to this long-standing challenge in synthetic biology.

First, the team developed a library of proof-of-concept genetic circuits. It then pooled the circuits and inserted them into human cells. Next, they used long-read and short-read DNA sequencing to create "a master map" that linked each circuit to how it performed.

The data was then used to train AI and machine learning models to analyze circuits and make accurate predictions for how untested circuits might perform.

“We end up with measurements for a lot of the possible designs but not all of them, and that is where building the (machine learning) model comes in,” O’Connell explained in the release. “We use the data to train a model that can understand this landscape and predict things we were not able to generate data on.”

Ultimately, the researchers believe the circuit characterization and AI-driven understanding can speed up synthetic biology, lead to faster development of biotechnology and potentially support more cell-based therapy breakthroughs by shedding new light on how gene circuits behave, according to Rice.

“We think AI/ML-driven design is the future of synthetic biology,” Bashor added in the release. “As we collect more data using CLASSIC, we can train more complex models to make predictions for how to design even more sophisticated and useful cellular biotechnology.”

The team at Rice also worked with Pankaj Mehta’s group in the department of physics at Boston University and Todd Treangen’s group in Rice’s computer science department. Research was supported by the National Institutes of Health, Office of Naval Research, the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation, the American Heart Association, National Library of Medicine, the National Science Foundation, Rice’s Ken Kennedy Institute and the Rice Institute of Synthetic Biology.

James Collins, a biomedical engineer at MIT who helped establish synthetic biology as a field, added that CLASSIC is a new, defining milestone.

“Twenty-five years ago, those early circuits showed that we could program living cells, but they were built one at a time, each requiring months of tuning,” said Collins, who was one of the inventors of the toggle switch. “Bashor and colleagues have now delivered a transformative leap: CLASSIC brings high-throughput engineering to gene circuit design, allowing exploration of combinatorial spaces that were previously out of reach. Their platform doesn’t just accelerate the design-build-test-learn cycle; it redefines its scale, marking a new era of data-driven synthetic biology.”